TY - JOUR T1 - ▼Olodaterol—another LABA for COPD JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 42 LP - 45 DO - 10.1136/dtb.2015.4.0319 VL - 53 IS - 4 A2 - , Y1 - 2015/04/01 UR - http://dtb.bmj.com/content/53/4/42.abstract N2 - ▼Olodaterol solution for inhalation (Striverdi Respimat—Boehringer Ingelheim) is a long-acting beta2 agonist (LABA) licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). This is the third LABA to be licensed in the UK for once-daily use for patients with COPD. DTB has previously reviewed the use of indacaterol and vilanterol in combination with fluticasone furoate (▼Relvar Ellipta).1,2 In this article we consider the evidence for olodaterol and whether it offers any advantages in the management of COPD. ER -